ArticleNPJ schizophrenia2021

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study.

Christoph U Correll et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.